Core Viewpoint - COSCIENS Biopharma Inc. has entered into a resolution agreement with Goodwood to reconstitute its board of directors, aiming to enhance shareholder value and corporate governance [2][3][5]. Board Reconstitution - The board now consists of six directors: Anthony J. Giovinazzo, Ulrich Kosciessa, Ronald W. Miller, Peter H. Puccetti, Robert A. Seager, and David Spear [3][4]. - The 2025 Annual Meeting has been postponed to June 30, 2025, to allow for the timely dissemination of management information [4]. Shareholder Support - Goodwood, which holds approximately 8.2% of COSCIENS' outstanding common shares (257,257 shares), has agreed to vote in favor of the re-election of the six directors at the upcoming meeting [4]. Governance Commitment - The Reconstituted Board is dedicated to strong corporate governance and effective oversight, with plans to actively review COSCIENS' prospects and opportunities [5]. Director Profiles - **Anthony J. Giovinazzo**: Over 45 years of executive experience, previously CEO of Cynapsus Therapeutics, instrumental in its successful IPO and acquisition [7][9]. - **Ulrich Kosciessa**: CEO of Photonamic GmbH, extensive experience in global pharmaceutical operations, and significant growth achievements [10][11]. - **Ronald W. Miller**: Former President and CEO of Hoffmann-La Roche Limited in Canada, with over 43 years in the pharmaceutical industry [12]. - **Peter H. Puccetti**: Founder and CIO of Goodwood Inc., known for leading activist campaigns to unlock shareholder value [13][14]. - **Robert A. Seager**: Specializes in shareholder disputes and corporate governance, currently a partner at Voorheis & Co. LLP [15][16]. - **David Spear**: Over 35 years in the healthcare industry, focusing on eyecare, and has co-founded multiple ventures [17].